{"created":"2021-03-01T06:12:23.617908+00:00","id":8379,"links":{},"metadata":{"_buckets":{"deposit":"d603c85c-0421-4b0b-b99a-c356d4599448"},"_deposit":{"id":"8379","owners":[],"pid":{"revision_id":0,"type":"depid","value":"8379"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00008379","sets":["453:456","471:537:538:892"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Advances in Lung Cancer Medical Treatment(Advances in the Treatment of Lung Cancer)"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"12","bibliographicPageEnd":"674","bibliographicPageStart":"670","bibliographicVolumeNumber":"130","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"従来非小細胞肺癌は化学療法への感受性が低く, 治療目標は治癒ではなく延命と症状緩和であった. しかし近年EGFR遺伝子変異やEML4-ALK融合遺伝子といったドライバー遺伝子が発見され, それを標的とした分子標的治療薬であるEGFRチロシンキナーゼ阻害薬, ALK阻害薬の投与により, 進行期であっても長期の生存が期待できるようになった. また, 本年2015年は自己免疫機能を高めて腫瘍を制御する免疫チェックポイント阻害薬ニボルマブが肺癌に承認された. 同薬剤は抗腫瘍T細胞応答を利用する新しい作用機序の薬剤で, 従来の標準治療を上回る効果を示しており, 今後更なる生存期間の延長が期待される.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"58604","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Okajima, Masaaki"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岡島, 正明"}],"nameIdentifiers":[{"nameIdentifier":"58603","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-06"}],"displaytype":"detail","filename":"130(12)_670-674.pdf","filesize":[{"value":"603.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"130(12)_670-674.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/8379/files/130(12)_670-674.pdf"},"version_id":"639b1a98-595e-4031-becc-f6df56d59d74"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"非小細胞肺癌","subitem_subject_scheme":"Other"},{"subitem_subject":"EGFR","subitem_subject_scheme":"Other"},{"subitem_subject":"ALK","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫チェックポイント","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"3 肺癌内科治療の進歩 : 分子標的薬を中心に（シンポジウム　肺癌治療の進歩, 第712回新潟医学会）","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"3 肺癌内科治療の進歩 : 分子標的薬を中心に（シンポジウム　肺癌治療の進歩, 第712回新潟医学会）"},{"subitem_title":"3 肺癌内科治療の進歩 : 分子標的薬を中心に（シンポジウム　肺癌治療の進歩, 第712回新潟医学会）","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","892"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-08-21"},"publish_date":"2017-08-21","publish_status":"0","recid":"8379","relation_version_is_last":true,"title":["3 肺癌内科治療の進歩 : 分子標的薬を中心に（シンポジウム　肺癌治療の進歩, 第712回新潟医学会）"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:42:42.875440+00:00"}